Boston Partners trimmed its position in STERIS plc (NYSE:STE – Free Report) by 0.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,495,902 shares of the medical equipment provider’s stock after selling 2,432 shares during the period. Boston Partners’ holdings in STERIS were worth $314,150,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also bought and sold shares of STE. OneAscent Financial Services LLC acquired a new position in shares of STERIS during the third quarter worth $335,000. OneAscent Family Office LLC lifted its holdings in shares of STERIS by 22.9% during the 3rd quarter. OneAscent Family Office LLC now owns 2,610 shares of the medical equipment provider’s stock valued at $548,000 after purchasing an additional 487 shares during the last quarter. Harbour Wealth Management Group Inc. lifted its holdings in shares of STERIS by 16.2% during the 3rd quarter. Harbour Wealth Management Group Inc. now owns 2,277 shares of the medical equipment provider’s stock valued at $478,000 after purchasing an additional 317 shares during the last quarter. Public Sector Pension Investment Board lifted its holdings in shares of STERIS by 134.3% during the 3rd quarter. Public Sector Pension Investment Board now owns 37,474 shares of the medical equipment provider’s stock valued at $8,160,000 after purchasing an additional 21,479 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its position in shares of STERIS by 8.4% in the 3rd quarter. Global Retirement Partners LLC now owns 2,018 shares of the medical equipment provider’s stock worth $424,000 after purchasing an additional 157 shares in the last quarter. 94.69% of the stock is owned by hedge funds and other institutional investors.
Insider Activity at STERIS
In related news, Director Mohsen Sohi sold 4,893 shares of the firm’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $253.22, for a total value of $1,239,005.46. Following the completion of the transaction, the director owned 24,305 shares in the company, valued at $6,154,512.10. This trade represents a 16.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Julia Madsen sold 2,046 shares of the firm’s stock in a transaction on Friday, November 13th. The stock was sold at an average price of $260.00, for a total value of $531,960.00. Following the completion of the transaction, the vice president owned 10,211 shares of the company’s stock, valued at $2,654,860. This trade represents a 16.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 12,819 shares of company stock valued at $3,274,011 in the last ninety days. Company insiders own 1.12% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts recently weighed in on STE shares. UBS Group dropped their target price on STERIS from $275.00 to $270.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Morgan Stanley raised STERIS from an “overweight” rating to a “buy” rating in a research report on Friday, November 13th. Wall Street Zen upgraded STERIS from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 14th. KeyCorp increased their price target on STERIS from $269.00 to $284.00 and gave the company an “overweight” rating in a research note on Friday, November 6th. Finally, Jefferies Financial Group raised STERIS from a “hold” rating to a “buy” rating and raised their price target for the stock from $232.00 to $305.00 in a report on Friday, November 13th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $283.50.
Read Our Latest Analysis on STERIS
STERIS Stock Up 0.9%
NYSE:STE opened at $259.66 on Thursday. The company has a current ratio of 2.05, a quick ratio of 1.44 and a debt-to-equity ratio of 0.23. STERIS plc has a twelve month low of $195.14 and a twelve month high of $269.44. The company has a market cap of $25.21 billion, a PE ratio of 30.80 and a beta of 0.86. The company’s 50 day moving average is $225.69 and its two-hundred day moving average is $224.58.
STERIS (NYSE:STE – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $2.94 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.26. The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.56 billion. STERIS had a net margin of 13.41% and a return on equity of 14.80%. The business’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the company posted $2.47 earnings per share. Analysts anticipate that STERIS plc will post 11.46 EPS for the current year.
STERIS Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 17th. Investors of record on Tuesday, November 17th will be given a $0.69 dividend. This represents a $2.76 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, November 17th. STERIS’s dividend payout ratio is presently 32.74%.
STERIS Company Profile
STERIS plc (NYSE: STE) provides infection prevention and procedural products and services for healthcare, pharmaceutical, research, and other industries. Its offerings include sterilizers, washers and other equipment used to clean and sterilize medical devices and surgical instruments, as well as products for operating rooms and endoscopy procedures. The company also provides equipment installation, maintenance, repair, and training, along with contract sterilization and laboratory testing services.
Featured Articles
- Five stocks we like better than STERIS
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE – Free Report).
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.
